Riccardo Lencioni

Hepatology · 2001–2021

A researcher in the Science corpus: 13 papers; trusts 2 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 171 citations into it; #24 of 151 by trust here, #16 by citations
• Epidemiology — 87 citations into it; #1,383 of 2,148 by trust here, #337 by citations
• Pathology and Forensic Medicine — 16 citations into it

Whom Riccardo Lencioni trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Llovet
2. Jordi Bruix1 , 2
3. M. Sherman
4. C. Lo

Who trusts Riccardo Lencioni overall

1. J. Llovet
2. Jordi Bruix1 , 2
3. Amit G. Singal
4. Peter R. Galle
5. Alejandro Forner1 , 2
6. M. Sherman
7. Michel Ducreux
8. María E. Reig1 , 2
9. A. Cheng

Papers from Riccardo Lencioni's perspective

Ordered by how strongly the researchers Riccardo Lencioni trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
3. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
4. Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
5. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
6. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
7. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
8. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
9. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
10. Prognostic prediction and treatment strategy in hepatocellular carcinoma (Hepatology)

Their papers

• Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma (2021) — 840 citations
• Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016) — 660 citations
• Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016) — 662 citations
• Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. (2014) — 921 citations
• Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer (2013) — 774 citations
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
• Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma (2010) — 4,176 citations
• Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (2009) — 1,558 citations
• Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) - Update 2008 (2008) — 869 citations
• Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) — 1,196 citations
• Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. (2005) — 842 citations
• Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. (2003) — 1,013 citations
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001) — 4,137 citations